461
Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.
 the patient: Subject; a progressive visual loss and loss of consciousness: Effect; led to death: Effect; MTX treatment: Treatment; subsequent Ara-C treatment: Treatment; within 3 weeks.: Treatment; meningeal tumor: Treatment.Disorder; MTX: Treatment.Drug; Ara-C: Treatment.Drug; 3 weeks.: Treatment.Time_elapsed; MTX: Combination.Drug; Ara-C: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 the patient: Subject; a progressive visual loss and loss of consciousness: Effect; led to death: Effect; MTX treatment: Treatment; subsequent Ara-C treatment: Treatment; within 3 weeks.: Treatment; meningeal tumor: Treatment.Disorder; MTX: Treatment.Drug; Ara-C: Treatment.Drug; 3 weeks.: Treatment.Time_elapsed; MTX: Combination.Drug; Ara-C: Combination.Drug